logo-loader
viewImmuPharma PLC

ImmuPharma jumps as follow-up study confirms safety of flagship lupus drug

After Lupuzor missed its primary endpoint in a phase III trial last year, ImmuPharma has been working hard to build a data package for the drug which it can take to regulators

lupus
If Lupuzor proves useful in a longer-term, ongoing study as well, ImmuPharma will feel it has a decent chance of getting the drug approved

ImmuPharma PLC’s (LON:IMM) flagship lupus drug has confirmed its “outstanding and robust safety profile” in a six-month extension study.

The follow-up study was designed to evaluate Lupuzor’s safety and tolerability, and the drug passed with flying colours, with no serious adverse events reported.

WATCH: Immupharma chairman details £2.66mln financing and open label extension study

On top of that, ImmuPharma was also able to show that a third of the patients taking the drug were in remission at the end of the study.

“We are delighted that Lupuzor has again confirmed its robust safety profile and we are confident that Lupuzor has the potential to bring a much-needed treatment to Lupus sufferers around the world,” said chairman Tim McCarthy.

Building knowledge of drug

The follow-up study came about after Lupuzor missed its primary endpoint in a phase III trial last year.

But the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody positive.

Since then, ImmuPharma has been building a data package for the drug in order to boost its chances of regulatory success further down the line.

As well as the extension study, 500 lupus sufferers are being given access to Lupuzor for the next two years as part of a managed access programme (MAP).

After the success of the latest study, if Lupuzor can prove itself again in the MAP, ImmuPharma will look to use the data to get full regulatory approval for the drug, something bosses have previously said they hope to achieve “in the medium term”.

Shares were up 6% to 14.3p in early deals on Friday.

Quick facts: ImmuPharma PLC

Price: 7.75 GBX

AIM:IMM
Market: AIM
Market Cap: £12.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

on 11/9/19

2 min read